Lv1
30 积分 2025-10-02 加入
6580 Inhibition of IGF-1 Receptor Signaling and Ocular Fibroblast Cell Growth by VRDN-001 vs Teprotumumab
6小时前
待确认
Advances of IGF-1R inhibitors in Graves’ ophthalmopathy
2天前
已完结
IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients
2天前
已完结
IgA Nephropathy: Epidemiology and Disease Risk Across the World
1个月前
已完结
Drugs in Development to Treat IgA Nephropathy
1个月前
已完结
Lactobacillus casei Cell Wall Extract and Production of Galactose-Deficient IgA1 in a Humanized IGHA1 Mouse Model
1个月前
已完结
Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease
2个月前
已完结
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials
2个月前
已完结
Targeting Thyroid-Stimulating Hormone Receptor: A Perspective on Small-Molecule Modulators and Their Therapeutic Potential
3个月前
已完结
The evolving landscape of Thyroid Eye Disease: present and future
3个月前
已完结
皖公网安备34019202002308
